Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $24.3 million.

  • Cumberland Pharmaceuticals' Total Current Liabilities fell 2180.15% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year decrease of 2180.15%. This contributed to the annual value of $31.6 million for FY2024, which is 1300.64% up from last year.
  • Cumberland Pharmaceuticals' Total Current Liabilities amounted to $24.3 million in Q3 2025, which was down 2180.15% from $24.0 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Total Current Liabilities high stood at $31.6 million for Q4 2024, and its period low was $17.9 million during Q3 2021.
  • Over the past 5 years, Cumberland Pharmaceuticals' median Total Current Liabilities value was $25.3 million (recorded in 2022), while the average stood at $25.1 million.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Total Current Liabilities crashed by 2503.36% in 2021 and then soared by 4824.36% in 2022.
  • Cumberland Pharmaceuticals' Total Current Liabilities (Quarter) stood at $19.3 million in 2021, then skyrocketed by 48.24% to $28.6 million in 2022, then dropped by 2.09% to $28.0 million in 2023, then grew by 13.01% to $31.6 million in 2024, then fell by 23.12% to $24.3 million in 2025.
  • Its last three reported values are $24.3 million in Q3 2025, $24.0 million for Q2 2025, and $25.5 million during Q1 2025.